Back

Changes in EPA and DHA during supplementation with Omega-3 fatty acids and incident cardiovascular events: secondary analysis from the OMEMI trial

27 August 2021 (20:42 - 20:51)
Organised by:
Congress Presentation Part of: Can we improve outcomes by targeting metabolic risk? Nutrition, Malnutrition and Heart Disease ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Professor Peder Langeland Myhre

Oslo University Hospital Rikshospitalet, Oslo (Norway)

4 More presentations in this session

Presentation thumbnail
Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies.
Professor M. Banach (Lodz, PL)
Abstract Slides Video
Presentation thumbnail
Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial
Doctor M. Segar (Houston, US)
Abstract Slides Video
Presentation thumbnail
Impact of early initiation of SGLT2 inhibitor on cardiovascular outcomes in diabetic patients with known atherosclerotic cardiovascular disease or risk factors: propensity score matched analysis
Doctor W. Sun (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial
Doctor F. Cosentino (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Can we improve outcomes by targeting metabolic risk?

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 20:42 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources